Start Smart For Your Baby Texting Program Wins Children's Health Award By Medicaid Health Plans of America

Published on:

 

ST. LOUIS, Nov. 3, 2014-- Centene Corporation (NYSE: CNC) announced today that its Start Smart For Your Baby® Texting Program was awarded the Children's Health Award by the Medicaid Health Plans of America (MHPA). The Best Practices Awards honor Medicaid health plans for their exemplary programs which have improved the health of Medicaid enrollees by ensuring high-quality care. 

The Start Smart For Your Baby Texting Program is a component of Centene's comprehensive Start Smart For Your Baby Care Management program. The Texting Program began in January 2012 and aims to improve maternal and infant health by providing timely heath information, resources and reminders to members during their pregnancy and continuing six months after birth. Specifically, the program's goals are to encourage breastfeeding and increase prenatal, postpartum and infant well-child visits for our Medicaid members.

"We are honored to be recognized by MHPA for the Start Smart For Your Baby Texting Program," said Dr. Amy Poole-Yaeger, Vice President, Medical Affairs for Centene. "Our team strives to continue delivering innovative programs for our members to make healthy decisions for themselves and their family."

Over the life of the program, more than 476,700 text messages have been sent out to over 37,000 different members across 16 health plans, and over 24,700 Texting Program participants have given birth to babies. Nearly 22,000 members are enrolled in the program.

Compared to those not in the program, members who received the Start Smart For Your Baby text messages had improved timeliness of prenatal care, higher rates of ongoing prenatal care, and higher rates of breastfeeding. Prenatal care and breastfeeding are important precursors to healthy pregnancies and healthy babies. Centene continues utilizing innovative approaches, including the Start Smart For Your Baby Texting Program, to engage members and convey important and relevant information to impact health behaviors and improve quality of care. 

About Centene Corporation
Centene Corporation, a Fortune 500 company, is a leading multi-line healthcare enterprise that provides programs and services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children's Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and Long Term Care (LTC), in addition to other state-sponsored/hybrid programs, and Medicare (Special Needs Plans). The Company operates local health plans and offers a range of health insurance solutions. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health, care management software, correctional systems healthcare, in-home health services, life and health management, managed vision, pharmacy benefits management, specialty pharmacy and telehealth services.

Logo - http://photos.prnewswire.com/prnh/20141030/155662LOGO

SOURCE Centene Corporation

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.